MDA-7/IL-24, a novel tumor suppressor/cytokine is ubiquitinated and regulated by the ubiquitin-proteasome system, and inhibition of MDA-7/IL-24 degradation enhances the antitumor activity

Cancer Gene Therapy

Volumn 15, Issue 1, 2008, Pages 1-8

  Gopalan, B ^a,c   Shanker, M ^a   Scott, A ^a   Branch, C D ^a   Chada, S ^b   Ramesh, R ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b Introgen Therapeutics Inc   (United States)

^c INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

Author keywords

Cytokine; IL 24; MDA 7; Proteasome; Tumor suppressor; Ubiquitin

Indexed keywords

ADENOVIRUS VECTOR; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BORTEZOMIB; CALPASTATIN; INTERLEUKIN 24; PD 150606; PROTEASOME; SMALL INTERFERING RNA; UBIQUITIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CANCER INHIBITION; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME SUBUNIT; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; LUNG CARCINOMA; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROCESSING; UBIQUITINATION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ADENOVIRIDAE; BORONIC ACIDS; CATALYTIC DOMAIN; CELL LINE, TUMOR; FEMALE; GENE THERAPY; HUMANS; INTERLEUKINS; LUNG NEOPLASMS; LYSOSOMES; OVARIAN NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; RNA, SMALL INTERFERING; TUMOR SUPPRESSOR PROTEINS; UBIQUITIN; UBIQUITINATION;

EID: 37149007876     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701095     Document Type: Article

References (29)

1. Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 2006; 24: 1241-1245.
2. Yang XJ, Gregoire S. A recurrent phospho-sumoyl switch in transcriptional repression and beyond. Mol Cell 2006; 23: 779-786.
3. Dahlmann B. Proteasomes. Essays Biochem 2005; 41: 31-48.
4. Reinstein E, Ciechanover A. Narrative review: protein degradation and human diseases: the ubiquitin connection. Ann Intern Med 2006; 145: 676-684.
5. Hirano Y, Ronai Z. A newfunction for p53 ubiquitination. Cell 2006; 127: 675-677.
6. Yamasaki S, Yagishita N, Sasaki T. Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase 'Synoviolin'. EMBO J 2007; 26: 113-122.
7. Trotman LC, Wang X, Alimonti Z. Ubiquitination regulates PTEN nuclear import and tumor suppression. Cell 2007; 128: 141-156.
8. den Besten W, Kuo ML, Tago K, Williams RT, Sherr CJ. Ubiquitination of, and sumoylation by, the Arf tumor suppressor. Isr Med Assoc J 2006; 8: 249-251.
9. Ying H, Xiao ZX. Targeting retinoblastoma protein for degradation by proteasomes. Cell Cycle 2006; 5: 506-508.
10. Brignole C, Marimpietri D, Pastorino F, Nico B, Di Paolo D, Cioni M et al. Effect of bortezomib on human neuroblastoma cell growth, apoptosis, and angiogenesis. Natl Cancer Inst 2006; 98: 1142-1157.
11. Roccaro AM, Hideshima T, Richardson PG, Russo D, Ribatti D, Vacca A et al. Bortezomib as an antitumor agent. Curr Pharm Biotechnol 2006; 7: 441-448.
12. Chada S, Sutton RB, Ekmekcioglu S, Ellerhorst J, Mumm JB, Leitner WW et al. MDA-7/IL-24 is a unique cytokine-tumor suppressor in the IL-10 family. Int Immunopharmacol 2004; 4: 649-667.
13. Fisher PB, Gopalkrishnan RV, Chada S, Ramesh R, Grimm EA, Rosenfeld MR et al. mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther 2003; 2: S23-S37.
14. Mhashilkar AM, Schrock RD, Hindi M, Liao J, Sieger K, Kourouma F et al. Melanoma differentiation associated gene-7 (mda-7): a novel anti-tumor gene for cancer gene therapy. Mol Med 2001; 7: 271-282.
15. Saeki T, Mhashilkar A, Chada S, Branch C, Roth JA, Ramesh R. Tumor-suppressive effects by adenovirus-mediated mda-7 gene transfer in non-small cell lung cancer cell in vitro. Gene Therapy 2000; 7: 2051-2057.
16. Pataer A, Vorburger SA, Barber GN, Chada S, Mhashilkar AM, Zou-Yang H et al. Adenoviral transfer of the melanoma differentiation-associated gene 7 (mda7) induces apoptosis of lung cancer cells via up-regulation of the double-stranded RNA-dependent protein kinase (PKR). Cancer Res 2002; 62: 2239-2243.
17. Gopalan B, Litvak A, Sharma C, Mhashilkar AM, Chada S, Ramesh R. Activation of the Fas-FasL signaling pathway by MDA-7/IL-24 kills human ovarian cancer cells. Cancer Res 2005; 65: 3017-3024.
18. Pataer A, Bocangel D, Chada S, Roth JA, Hunt KK, Swisher SG. Enhancement of adenoviral MDA-7-mediated cell killing in human lung cancer cells by geldanamycin and its 17-allyl- amino-17-demethoxy analogue. Cancer Gene Ther 2007; 14: 2-18.
19. Nishikawa T, Ramesh R, Munshi A, Chada S, Meyn RE. Adenovirus-mediated mda-7 (IL24) gene therapy suppresses angiogenesis and sensitizes NSCLC xenograft tumors to radiation. Mol Ther 2004; 9: 818-828.
20. Shanker M, Gopalan B, Patel S, Bocangel D, Chada S, Ramesh R. Vitamin E succinate in combination with mda-7 results in enhanced human ovarian tumor cell killing through modulation of extrinsic and intrinsic apoptotic pathways. Cancer Lett 2007; 254: 217-226.
21. Oida Y, Gopalan B, Miyahara R, Inoue S, Branch CD, Mhashilkar AM et al. Sulindac enhances adenoviral vector expressing mda-7/IL-24-mediated apoptosis in human lung cancer. Mol Cancer Ther 2005; 4: 291-304.
22. Inoue S, Hartman A, Branch CD, Bucana CD, Bekele BN, Stephens LC et al. mda-7 in combination with bevacizumab treatment produces a synergistic and complete inhibitory effect on lung tumor xenograft. Mol Ther 2007; 15: 287-294.
23. Ramesh R, Ito I, Saito Y, Wu Z, Mhashikar AM, Wilson DR et al. Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery. DNA Cell Biol 2004; 23: 850-857.
24. Tahara I, Miyake K, Hanawa H, Kurai T, Hirai Y, Ishizaki Met al. Systemic cancer gene therapy using adeno-associated virus type 1 vector expressing MDA-7/IL24. Mol Ther 2007 [E-pub ahead of print].
25. Ramesh R, Mhashilkar AM, Tanaka F, Saito Y, Branch CD, Sieger K et al. Melanoma differentiation-associated gene 7/interleukin (IL)-24 is a novel ligand that regulates angiogenesis via the IL-22 receptor. Cancer Res 2003; 63: 5105-5113.
26. Ward CL, Omura S, Kopito RR. Degradation of CFTR by the ubiquitin-proteasome pathway. Cell 1995; 83: 121-127.
27. Murata S. Multiple chaperone-assisted formation of mammalian 20S proteasomes. IUBMB Life 2006; 58: 344-348.
28. Zhu H, Guo W, Zhang L, Wu S, Teraishi F, Davis JJ et al. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol Ther 2005; 4: 781-786.
29. Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM et al. Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms. Anticancer Res 2006; 26: 1869-1876.